RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20151126
DO 10.1101/2020.07.14.20151126
A1 Wajnberg, Ania
A1 Amanat, Fatima
A1 Firpo, Adolfo
A1 Altman, Deena R.
A1 Bailey, Mark J.
A1 Mansour, Mayce
A1 McMahon, Meagan
A1 Meade, Philip
A1 Mendu, Damodara Rao
A1 Muellers, Kimberly
A1 Stadlbauer, Daniel
A1 Stone, Kimberly
A1 Strohmeier, Shirin
A1 Aberg, Judith
A1 Reich, David L.
A1 Krammer, Florian
A1 Cordon-Cardo, Carlos
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.14.20151126.abstract
AB SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Questions regarding the robustness, functionality and longevity of the antibody response to the virus remain unanswered. Here we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein, based on a dataset of 19,860 individuals screened at Mount Sinai Health System in New York City. We also show that titers are stable for at least a period approximating three months, and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggests that more than 90% of seroconverters make detectible neutralizing antibody responses and that these titers are stable for at least the near-term future.One Sentence Summary Antibody responses induced by natural mild-to-moderate SARS-CoV-2 infection are robust, neutralizing and are stable for at least 3 months.Competing Interest StatementMount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays.Funding StatementThis work was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (FK), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (FK), and the generous support of the JPB foundation, the Open Philanthropy Project (#2020-215611) and other philanthropic donations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mount Sinai Hospital Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is available from the corresponding authors upon reasonable request.